Invivodata Captures Primary Efficacy Data In Largest Controlled Allergy Vaccine Trial

invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced that its DiaryPRO® field-based ePRO system was used to capture primary efficacy endpoint data in the recently unblinded Phase III study of Pollinex® Quattro, a vaccine being developed by Allergy Therapeutics® plc (AIM:AGY) to treat the symptoms of seasonal allergic rhinoconjunctivitis (SAR).

More: continued here

Filed under: Allergies on June 19th, 2008